Tolvaptan (a vasopressin V2 receptor antagonist) is used in hyponatremia. In which specific type of hyponatremia is tolvaptan most efficacious, and why is it contraindicated in hypovolemic hyponatremia?

• A Euvolemic/hypervolemic hyponatremia (SIADH, CHF, cirrhosis) — V2 blockade causes aquaresis (water without sodium loss); in hypovolemic states, ADH release is appropriately compensatory and blocking V2 prevents renal water conservation, worsening dehydration and causing excessively rapid sodium correction with risk of osmotic demyelination ✓
• B Hypovolemic hyponatremia — aquaresis compensates for sodium depletion by reducing total body water without further sodium loss
• C All types of hyponatremia — tolvaptan's selectivity for V2 over V1 prevents any hemodynamic effects and is safe regardless of volume status
• D Hypervolemic hyponatremia only — V2 blockade is contraindicated in euvolemic states because it causes paradoxical SIADH by triggering compensatory ADH hypersecretion

Explanation

Tolvaptan and conivaptan are vaptans that competitively block renal V2 receptors on the collecting duct principal cells, preventing ADH-mediated aquaporin-2 insertion and water reabsorption. This causes free water excretion (aquaresis — electrolyte-free water diuresis) without significant sodium loss, raising serum sodium. They are indicated for euvolemic hyponatremia (SIADH) and hypervolemic hyponatremia (CHF, cirrhosis) where ADH secretion is inappropriate or maladaptive. They are specifically CONTRAINDICATED in hypovolemic hyponatremia because in that setting, ADH secretion is appropriate and compensatory — blocking it causes unrestrained water loss, worsens hypovolemia, and can trigger excessively rapid sodium correction leading to osmotic demyelination syndrome (central pontine myelinolysis). Tolvaptan has a black box warning for rapid overcorrection of sodium (>12 mEq/L in 24 hours) and hepatotoxicity at high doses (TEMPO trial).

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.